Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia

被引:29
作者
Glick, Ira D.
Pham, Diana
Davis, John M.
机构
[1] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA
[2] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA
关键词
D O I
10.4088/JCP.v67n0813
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: There are virtually no controlled data suggesting that concomitant psychotropic medications (CPMs) improve outcome in schizophrenia after the acute phase. Despite that, polypharmacy (with all of its disadvantages) is far more common than monotherapy. To our knowledge, there have been no published reports of prospective systematic investigations of the efficacy of unrestricted CPM use in nonacute schizophrenia. Method: This was a naturalistic, systematic study using a sample of 53 stabilized patients with DSM-IV-TR schizophrenia from 1 clinical practice setting including both private patients and patients from controlled research studies of the effectiveness of antipsychotics. Since there are meager controlled or systematic data on the effectiveness of CPM use with antipsychotics in nonacute schizophrenia, we tested the clinical strategy of CPM use by gradually tapering all CPMs (except antianxiety agents). The aim was to determine if the CPM improved outcome, had no effect, or worsened outcome using the Clinical Global Impressions-Improvement scale before and after taper, over at least 3 months and in some cases up to 18 months after discontinuation. Data were gathered from July 2002 to June 2005. Results: For 21 patients undergoing 22 antidepressant tapers, no change was noted in 18 of 22 tapers, while in 3 improvement was noted and in 1 worsening was noted. For the 12 patients on treatment with mood stabilizers, no change was noted in 10 of 13 discontinuations, while in 3 mild worsening was noted. One patient was on treatment with both modafinil and trazodone and reported no change after tapering each in separate discontinuation trials, while another 3 patients were taking sleeping medications and also noted no change after discontinuation. Conclusion: For most stabilized, chronic patients with schizophrenia, tapering adjunctive medications did not change outcome. This naturalistic study further defines the limits of efficacy of some concomitant classes of medications in patients with chronic schizophrenia who are already receiving adequate antipsychotic therapy.
引用
收藏
页码:1261 / 1265
页数:5
相关论文
共 18 条
[1]  
BASAN C, 2004, COCHRANE DB SYST REV
[2]   Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia [J].
Casey, DE ;
Daniel, DG ;
Wassef, AA ;
Tracy, KA ;
Wozniak, P ;
Sommerville, KW .
NEUROPSYCHOPHARMACOLOGY, 2003, 28 (01) :182-192
[3]   Hopelessness as a predictor of work functioning among patients with schizophrenia [J].
Davis, LW ;
Nees, MA ;
Hunter, NL ;
Lysaker, PH .
PSYCHIATRIC SERVICES, 2004, 55 (04) :434-436
[4]   Morphine, gabapentin, or their combination for neuropathic pain [J].
Gilron, I ;
Bailey, JM ;
Tu, DS ;
Holden, RR ;
Weaver, DF ;
Houlden, RL .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (13) :1324-1334
[5]   Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder [J].
Glick, ID ;
Marder, SR .
JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (05) :638-641
[6]  
Guy W., 1976, ECDEU ASSESSMENT MAN, P217, DOI DOI 10.1016/J.BIOPHA.2016.11.034
[7]   Psychopharmacology - Rational and irrational polypharmacy [J].
Kingsbury, SJ ;
Yi, D ;
Simpson, GM .
PSYCHIATRIC SERVICES, 2001, 52 (08) :1033-+
[8]  
Lehman AF, 2004, AM J PSYCHIAT, V161, P1
[9]  
LEUCHT S, 2002, COCHRANE LIB
[10]   Assessing demoralization and depression in the setting of medical disease [J].
Mangelli, L ;
Fava, GA ;
Grandi, S ;
Grassi, L ;
Ottolini, F ;
Porcelli, P ;
Rafanelli, C ;
Rigatelli, M ;
Sonino, N .
JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (03) :391-394